---
title: "Aligos Therapeutics ernennt Nikhil Aneja zum Principal Accounting Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274867162.md"
datetime: "2026-02-04T21:10:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274867162.md)
  - [en](https://longbridge.com/en/news/274867162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274867162.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274867162.md) | [繁體中文](https://longbridge.com/zh-HK/news/274867162.md)


# Aligos Therapeutics ernennt Nikhil Aneja zum Principal Accounting Officer

Aligos Therapeutics Inc. hat bekannt gegeben, dass Nikhil Aneja ab sofort als Principal Accounting Officer des Unternehmens ernannt wurde. Er folgt auf Lesley Ann Calhoun, die weiterhin als Executive Vice President, Chief Operating Officer und Chief Financial Officer tätig ist. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-037558), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Aligos Therapeutics, Inc. (ALGS.US)](https://longbridge.com/en/quote/ALGS.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/en/news/278442392.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/en/news/278566951.md)